Cost saving and predictive factors of response to rituximab in rheumatoid arthritis, including the IL-6 promoter gene polymorphism

Italian Journal of Public Health

Volumn 9, Issue 4, 2012, Pages

  Quartuccio, Luca ^a   Salvin, Sara ^a   Fabris, Martina ^a   Benucci, Maurizio ^b   Pellerito, Raffaele ^c   Furian, Cristina ^a   Masolini, Paola ^a   Cimmino, Marco ^d   Troncon, Maria Grazia ^a   Guarrera, Giovanni Maria ^a   De Vita, Salvatore ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b Ospedale San Giovanni di Dio   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Biologics; Pharmacogenetic; Quality of life; Rheumatoid arthritis; Rituximab

Indexed keywords

EID: 84871543677     PISSN: 17237815     EISSN: None     Source Type: Journal    
DOI: 10.2427/8696     Document Type: Article

References (35)

1. Salaffi F, De Angelis R, Grassi W.M Arche Pain Prevalence; Investigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional communitybased study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23: 819-28
2. Leardini G, Salaffi F, Montanelli R, et al. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002; 20: 505-5
3. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39
4. Cohen S. Small molecular therapies for rheumatoid arthritis: where do we stand? Expert Opin Investig Drugs 2012; 21: 23-31
5. Scherer HU, Dörner T, Burmester GR. Patient-tailored therapy in rheumatoid arthritis: an editorial review. Curr Opin Rheumatol 2010; 22: 237-45
6. Gibson DS, Rooney ME, Finnegan S, et al. Biomarkers in rheumatology, now and in the future. Rheumatology (Oxford) 2012; 51: 423-33
7. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45
8. De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46: 2029-33
9. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81
10. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806
11. Quartuccio L, Lombardi S, Fabris M, et al. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Ann N Y Acad Sci 2009; 1173: 692-700
12. Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1557-9
13. Fabris M, Quartuccio L, Lombardi S, et al. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 2012; 11: 315-20
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24
15. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56: 3896-908
16. Bansback NJ, Brennan A, Ghatnekar O. Costeffectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005; 64: 995-1002
17. Burmester GR. RA in 2011: Advances in diagnosis, treatment and definition of remission. Nat Rev Rheumatol 2012; 8:65-6
18. Filipovic I, Walker D, Forster F, Curry AS. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1083-90
19. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol 2010; 28(3 Suppl 59): S32-40
20. Puolakka K, Kautiainen H, Möttönen T, et al., FINRACo Trial Troup. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 2005; 64: 130-3
21. Fries J, Spitz P, Kraines R, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45
22. Torrance G. Measurement of health state utilities for economic appraisal. A review. J Health Econ 1986; 5: 1-30
23. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al.; GISEA group. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007; 34: 1670-3
24. Benucci M, Iannazzo S, Zaniolo O, Sabadini L. Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis. Clin Exp Rheumatol 2010; 28: 722-7
25. Benucci M, Saviola G, Baiardi P, Manfredi M. Costeffectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life. Rheumatol Int 2011; 31: 1465-9
26. Launois R, Payet S, Saidenberg-Kermanac N, et al. Budget impact model of rituximab after failure of one or more TNFa inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008; 65: 288-95
27. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19: 1103-9
28. Towse A, Pritchard C. National Institute for Clinical Excellence (NICE): Is economic appraisal working? Pharmacoeconomics 2002; 20 Suppl 3: 95-105
29. Messori A, Santarlasci B, Trippoli S, et al. Clinicaleconomic appropriateness of drug treatments: designing a method that combines evidence-based information and cost assessments to construct league tables accounting for the potential number of patients. Expert Opin Pharmacother 2004; 5: 2381-9
30. Tyagi V, Singh SK, Sawhney A, et al. Using gross national product to calculate acceptable immunisation costs: deploying cost-effectiveness calculations in reverse. Pharmacoeconomics 2003; 21: 497-9
31. Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 2012; 24: 319-26
32. Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2012 Jul 13. doi:10.1136/annrheumdis-2012-201456 [Epub ahead of print]
33. Horton SC, Walsh CA, Emery P. Established rheumatoid arthritis: rationale for best practice physician' perspective of how to realize tight control in clinical practice. Best Pract Res Clin Rheumatol 2011; 25: 509-21
34. Fabris M, Quartuccio L, Vital E, et al. The TTTT BLyS promoter haplotype associates with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to TNF blockers. Arthritis Rheum 2012 Sep 22. doi: 10.1002/art.37707. [Epub ahead of print]
35. Quartuccio L, Schiavon F, Biasi D, et al. 12-month retrospective analysis of two different Rituximab retreatment regimens in rheumatoid arthritis: retreatment at clinical relapse vs 6-month fixed retreatment. Arthritis Rheum 2011; 63: S868